Posted On: 01/10/2014 12:19:20 PM
Post# of 63821
$NBIX gapped into a double $18.63
Shares Outstanding 67,343,394 a/o Oct 23, 2013
Float Not Available
Neurocrine Announces 12-Week Safety Results From Initial Phase IIB Study Of VMAT2 Inhibitor NBI-98854
1/9/2014 4:31:00 PM - PR Newswire
Healthcare Companies Report Conference Presentation Schedule, Stock Price Updates, and Clinical Study Results - Research Report on Medivation, Envision Healthcare, Fonar, Idera Pharma, and Neurocrine
1/9/2014 8:00:00 AM - PR Newswire
Kinect-2 Puts '854 Back Into Play For Neurocrine
1/8/2014 9:50:00 AM - Seeking Alpha
Increasing Price Target On Neurocrine Bio After Phase 2 Success
1/8/2014 9:34:00 AM - Seeking Alpha
Mid-Afternoon Market Update: Markets Post Large Rally as Textron Falls on Citron Report
1/7/2014 3:43:33 PM - Benzinga
Shares Outstanding 67,343,394 a/o Oct 23, 2013
Float Not Available
Neurocrine Announces 12-Week Safety Results From Initial Phase IIB Study Of VMAT2 Inhibitor NBI-98854
1/9/2014 4:31:00 PM - PR Newswire
Healthcare Companies Report Conference Presentation Schedule, Stock Price Updates, and Clinical Study Results - Research Report on Medivation, Envision Healthcare, Fonar, Idera Pharma, and Neurocrine
1/9/2014 8:00:00 AM - PR Newswire
Kinect-2 Puts '854 Back Into Play For Neurocrine
1/8/2014 9:50:00 AM - Seeking Alpha
Increasing Price Target On Neurocrine Bio After Phase 2 Success
1/8/2014 9:34:00 AM - Seeking Alpha
Mid-Afternoon Market Update: Markets Post Large Rally as Textron Falls on Citron Report
1/7/2014 3:43:33 PM - Benzinga
(0)
(0)
